Path ID: DB00933_MESH_D012559_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| DB:DB00933 | Mesoridazine | Drug |
| UniProt:P28223 | 5-hydroxytryptamine receptor 2A | Protein |
| UniProt:P14416 | D(2) dopamine receptor | Protein |
| MESH:D004298 | Dopamine | ChemicalSubstance |
| HP:0000716 | Depressivity | PhenotypicFeature |
| GO:0061527 | Dopamine secretion, neurotransmission | BiologicalProcess |
| MESH:D012559 | Schizophrenia | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Mesoridazine | DECREASES ACTIVITY OF | 5-Hydroxytryptamine Receptor 2A |
| Mesoridazine | DECREASES ACTIVITY OF | D(2) Dopamine Receptor |
| 5-Hydroxytryptamine Receptor 2A | POSITIVELY CORRELATED WITH | Depressivity |
| Depressivity | MANIFESTATION OF | Schizophrenia |
| D(2) Dopamine Receptor | POSITIVELY CORRELATED WITH | Dopamine |
| Dopamine | POSITIVELY CORRELATED WITH | Dopamine Secretion, Neurotransmission |
| Dopamine Secretion, Neurotransmission | AFFECTED BY | Schizophrenia |
Comment: Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.
Reference: